Skip to content
DataLookout
Menu

EXCALIBUR1+2NCT04898504

HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Following temporary halt of inclusion in September 2024, several measures were taken, as previuosly reported. As numbers included by September 2024 were sufficient to conclude for primary endpont, we have decided not to restart the trial. Show 6 more changesShow less
    • Primary completion date changed from estimate of May 2025 to Aug 20, 2026
    • Eligibility criteria expanded, about 30 words
    • Final enrollment: 39 participants (planned 45)
    • Secondary endpoints: details revised at 2 of 4 entries
    • Site details revised
    • Publications: details revised at 13 of 13 entries
  2. Notable Primary completion date: May 2024 to May 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  3. Notable Eligibility criteria expanded, about 302 wordsv3 Show 4 more changesShow less
    • Start date changed from estimate of Aug 2021 to Aug 23, 2021
    • Study description revised
    • Site contact updated
    • Study title expanded, about 1 word
  4. Notable Start date: May 2021 to Aug 2021v2
  5. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Overall survival at 2 years
Timeframe: 2 years

Secondary (4)

Quality of Life by using QLQ-C30
Operative complications
Postoperative morbidity and mortality
Quality of life using EQ-5D-5L

Arms and interventions

Next line chemotherapy onlyNo intervention

Next line chemotherapy is the current standard treatment for patients with CRLM and progression on chemotherapy. We will include 18 patients in this treatment arm.

Liver transplantActive comparator

Liver transplant (LTX) has emerged as a possible solution for some patients with unresectable CRLM who otherwise have good prognosis based on available scorings systems. We will include 9 patients in this treatment arm. They will be given next line chemotherapy followed by Liver-Tx.

Hepatic artery infusion (HAI) chemotherapyActive comparator

The biological rationale for intra-arterial chemotherapy is that the hepatic artery rather than the portal vein is responsible for most of the blood supply to liver tumors. We will include 18 patients in this arm

Drugs: Floxuridine

Procedures: Liver Transplantation

Sites

1 site in 1 country

  • Oslo University HospitalOslo, Oslo, Norway